Abstract
Objectives
Botulinum neurotoxin type A (BNT-A) intrasalivary gland injections in patients with neurological disorders have been known to effectively treat hypersalivation. However, oral health can be compromised with increasing the dose. The aim of this study was to find out the therapeutic effect of low-dose, ultrasonography-controlled BNT-A injections into the bilateral parotid and submandibular glands on oral health in the treatment of sialorrhea.
Material and methods
Twenty patients diagnosed with Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and other neurological disorders, including stroke or birth trauma, received BNT-A injections with salivary tests before and 1 month after the injections. Drooling was evaluated using subjective scales and objective assessment of salivary flow rate and oral health (salivary composition and cariogenic bacterial counts).
Results
A significant decrease was found in salivary flow rate at 1- and 3-month follow-up in the BNT-A treated group. There was no significant change in salivary composition or cariogenic bacterial counts.
Conclusion
BNT-A injections according to the current protocol can effectively manage sialorrhea while maintaining oral health.
Clinical relevance
Oral health can be considered the mirror of general human health, as the cause of many diseases. Saliva plays a crucial role in protecting the oral cavity. The present study is of high clinical relevance because, although earlier research has proved the effect of Botulinum neurotoxin type A injections on reduction in saliva flow, data about the risks of the treatment method to the oral condition through affecting saliva composition has so far been missing.
Similar content being viewed by others
References
Daugherty KK (2007) Botulinum toxin A in the treatment of sialorrhea. Benson J 41:79–85
Taba P, Asser T (2002) Prevalence of Parkinson’s disease in Estonia. Acta Neurol Scan 106(5):276–81
Mancini F, Zangaglia R, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685–688
Katie P-HW, Ke J-Y, Chen C-Y, Chen C-L, Chou M-Y, Pei Y-C (2011) Botulinum toxin type a on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol 26:838–843
Weikamp JG, Schinagl DA, Verstappen CC, Schelhaas HJ, de Swart BJ, Kalf JG (2016) Botulinum toxin-A injections vs radiotherapy for drooling in ALS. Acta Neurol Scand. doi:10.1111/ane.12559
Heintze U, Birkhed D, Björn H (1983) Secretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sex. Swed Dent J 7(6):227–38
López-Jornet P, Bermejo-Fenoll A, Bagán-Sebastian JV, Pascula Gómez E (1996) Comparison of a new test for the measurement of resting whole saliva with the draining and the swab techniques. Braz Dent J 7:81–6
Jongerius PH, van den Hoogen FJ, van Limbeek J et al (2004) The effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 114:620–627
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG (2006) Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 21:704–707
Pienihäkkinen K, Jokela J (1995) A simple method for monitoring mutans streptococci in young children. Eur J Oral Sci 103:61–2
Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–70
Christian A, Bardac DI (2013) Effects of occupational hazards on saliva. AMT 2(1):293–295
Thorild I, Lindau-Jonson B, Twetman S (2002) Prevalence of Streptococcus mutans in mothers and in their preschool children. Int J Paediatr Dent 12:2–7
Petersson H, Twetman S, Bratthall D (2002) Evaluation of a computer program for caries risk assessment in schoolchildren. Caries Res 36:327–40
Crossner C-G, Hagberg C (1977) A clinical and microbiological evaluation of the dentocult dip-slide test. Swed Dent J 1:85–94
Birkhed D, Edwardsson S, Andersson H (1981) Comparison among a dip-slide test (Dentocult), plate count, and Snyder test for estimating number of lactobacilli in human saliva. J Dent Res 60:1832–40
Schlagenhauf U, Pommerencke K, Weiger R (1995) Influence of toothbrushing, eating and smoking on Dentocult® SM Strip mutans test scores. Oral Microbiol Immunol 10:98–101
Wilken B, Aslami B, Backes H (2008) Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 39:200–4
Sriskandan N, Moody A, Howlett DC (2010) Ultrasound-guided submandibular gland injection of botulinum toxin for hypersalivation in cerebral palsy. Br J Oral Maxillofac Surg 48:58–60
Suskind DL, Tilton A, Suskind DL, Tilton A (2002) Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 112:73–81
Fuster Torres MA, Berini Aytes L, Gay Escoda C et al (2007) Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal 12:E511–E517
Gopinath VK, Arzreanne AR (2006) Saliva as a diagnostic tool for assessment of dental caries. Arch Orofac Sci 1:57–59
Cicciù M, Risitano G, Lo Giudice G, Bramanti E (2012) Periodontal health and caries prevalence evaluation in patients affected by Parkinson’s disease. Parkinsons Dis 2012:541908. doi:10.1155/2012/541908
Sharma E, Vishwanathamurthy RA, Nadella M, Savitha AN, Gundannavar G, Hussain MA (2012) A randomised study to compare salivary pH, calcium, phosphate and calculus formation after using anticavity dentifrices containing Recaldent(®) and functionalized tri-calcium phosphate. J Indian Soc Periodontol 16:504–7
Brambilla E, Twetman S, Felloni A et al (1999) Salivary mutans streptococci and lactobacilli in 9- and 13-year-old Italian schoolchildren and the relation to oral health. Clin Oral Investig 3:7–10
Crossner C-G, Claesson R, Johansson T (1989) Presence of mutans streptococci and various types of lactobacilli in interdental spaces related to development of proximal carious lesions. Scand J Dent Res 97:307–15
Gabre P, Martinsson T, Gahnberg L (1999) Simplified sampling methods for estimating levels of lactobacilli in saliva in dental clinical practice. Acta Odontol Scand 57:181–4
Larmas M (1975) A new dip-slide method for the counting of salivary lactobacilli. Proc Finn Dent Soc 71:31–5
Parvinen T (1984) Flow rate, pH, and Lactobacillus and yeast counts of stimulated whole saliva in adults [dissertation]. University of Turku, Turku, Finland
Larmas M (1992) Saliva and dental caries: diagnostic tests for normal dental practice. Int Dent J 42:199–208
Pradeep AR, Singh SP, Martande SS, Raju AP, Rustagi T, Suke DK, Naik SB (2013) Clinical evaluation of the periodontal health condition and oral health awareness in Parkinson’s disease patients. Gerodontology doi. doi:10.1111/ger.12055
Erbe C, Klukowska M, Tsaknaki I, Timm H, Grender J, Wehrbein H (2013) Efficacy of 3 toothbrush treatments on plaque removal in orthodontic patients assessed with digital plaque imaging: a randomized controlled trial. Am J Orthod Dentofacial Orthop 143:760–6
Prendergast V, Jakobsson U, Renvert S, Hallberg IR (2012) Effects of a standard versus comprehensive oral care protocol among intubated neuroscience ICU patients: results of a randomized controlled trial. J Neurosci Nurs 44:134–46
Rath SK, Singh M (2013) Comparative clinical and microbiological efficacy of mouthwashes containing 0.2% and 0.12% chlorhexidine. Dent Res J (Isfahan) 10:364–9
Authors roles
The study was conceived and designed by Janne Tiigimäe-Saar, Pille Taba, and Tiia Tamme. Acquisition, analysis, and interpretation of the data were performed by Janne Tiigimäe-Saar. Critical revision of the manuscript was made by Pille Taba and Tiia Tamme.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Funding
The study was supported by grant 3.2.1001.11-0017 of the EU European Regional Development Fund and by grant IUT2-4 of the Estonian Research Council (ETF 9255 2012–2015).
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. (State Agency of Medicines reference number is 15-024. Research Ethics Committee of the University of Tartu Protocol nr is 247/M-1.)
Informed consent
Informed consent was obtained from all individual participants included in the study.
Appendix
Appendix
Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (Goetz et al., 2008).
Part I: non-motor aspects of experiences of daily living
Item 2.2: SALIVA & DROOLING: Over the past week, have you usually had too much saliva during when you are awake or when you sleep?
-
0: Normal: Not at all (no problems).
-
1: Slight: I have too much saliva, but do not drool.
-
2: Mild: I have some drooling during sleep, but none when I am awake.
-
3: Moderate: I have some drooling when I am awake, but I usually do not need tissues or a handkerchief.
-
4: Severe: I have so much drooling that I regularly need to use tissues or a handkerchief to protect my clothes.
Rights and permissions
About this article
Cite this article
Tiigimäe-Saar, J., Taba, P. & Tamme, T. Does Botulinum neurotoxin type A treatment for sialorrhea change oral health?. Clin Oral Invest 21, 795–800 (2017). https://doi.org/10.1007/s00784-016-1826-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00784-016-1826-z